Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
Francesco Passamonti1, Martin Griesshammer2, Francesca Palandri3, Miklos Egyed4, Giulia Benevolo5, Timothy Devos6, Jeannie Callum7, Alessandro M Vannucchi8, Serdar Sivgin9, Caroline Bensasson10, Mahmudul Khan11, Nadjat Mounedji12, Guray Saydam13
1Department of Hematology, University of Insubria, Varese, Italy
2Department of Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Clinic, Minden, Germany
3Department of Hematology/Oncology, Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
4Hematology Department of Somogy County, Kaposi Mor Teaching Hospital, Kaposvar, Hungary
5Department of Hematology, Città della Salute e della Scienza di Torino, Turin, Italy
6Laboratory of Experimental Transplantation, Department of Microbiology and Immunology and Department of Hematology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
7Department of Transfusion Medicine and Tissue Banks, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
8Department of Experimental and Clinical Medicine, Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Florence, Italy
9Department of Hematology, Dedeman Stem Cell Transplantation Hospital, Erciyes University, Kayseri, Turkey
10Department of Clinical Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
11Department of Biostatistics, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
12Department of Oncology, Novartis Pharma S.A.S., Rueil-Malmaison, France
13Department of Hematology, Ege University Medical Faculty, Izmir, Turkey
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
The Lancet Oncology
Tập 18
88-99
Thông tin tác giả